NeuroQuest is developing a simple blood test for early diagnosis of Alzheimer’s disease.

The Technology & Approach

NeuroQuest has discovered blood-based immune biomarkers in Alzheimer’s patients that measure unique aspects of the immune system that reflect the disease pathology and can be used for diagnosis, prognosis, and monitoring of disease progression. These patented biomarkers may provide a better understanding of the mechanism of neurodegenerative disease, leading to improved therapeutics.

NeuroQuest is developing a simple blood screening test for populations aged 60 and older based on the peripheral immune system to address the urgent need for an accurate diagnostic test to enable early treatment. The test will serve as an affordable, accurate, accessible surrogate to PET scans, indicating formation of brain amyloid plaques in the preclinical stage of Alzheimer’s.

Biomarker tests will be essential to identify which individuals are in the early stages of Alzheimer’s and should receive disease-modifying treatment. Read more about the idea behind NeuroQuest.


Stage: Business development
Founded: 2009
Investors: The Trendlines Group, InterTech Group, South Carolina Research Authority, SC Launch, Maryland-Israel Trendlines Fund
IP: Exclusive rights to two international provisional patents


Renowned researchers backed by substantive, peer-reviewed literature and licensed IP combine to form the foundation of NeuroQuest’s blood test. The test is designed to detect the participation of the blood’s immune cells in the maintenance of proper brain activity, supportive healing and repair of neuronal damage — processes referred to as protective autoimmunity. This repair process is achieved through a disease-specific cellular immune response that can be measured in the peripheral blood.

A successful 2013 exploratory/independent clinical study confirming NeuroQuest’s platform technology performed by Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) further substantiated our approach yielding more than 90% sensitivity and 80% specificity in diagnosis of beta-amyloid positive.

In November 2015, NeuroQuest contracted with the Alzheimer’s Disease Cooperative Study at the University of California, San Diego to oversee collection and processing of 700 samples for their U.S. clinical trial.

In the Media

The Team

  • Etai Gilboa, PhD, Chairman: Extensive experience in international business development, with a focus on medical device companies; director of several medical device companies; PhD, social science, University of Haifa
  • Prof. Michal Schwartz, Scientific Advisor: Chair and VP, International Society of Neuroscience, Weizmann Institute of Science; serves on scientific advisory boards of global health organizations, a frequent lecturer and presenter, published extensively; founder, ProNeuron Biotech; Ph.D., chemical immunology, Weizmann Institute
  • Jacobo Mintzer, MD, MBA, VP Clinical Affairs: Professor of psychiatry, neurology, physiology, and neuroscience at the Medical University of South Carolina; conducted more than 250 clinical trials in Alzheimer’s; serves on boards of numerous Alzheimer’s organizations

Trendlines’ directors: Todd Dollinger, Steve Rhodes

Background & Market

Worldwide, nearly 47 million people have Alzheimer’s disease or a related form of dementia. Despite intense efforts by the medical community, current tests used to diagnose Alzheimer’s in its early stages — when intervention offers the most hope — have limited use due to their costs and reliability.

According to Alzheimer’s Disease International, the global cost of Alzheimer’s and dementia is estimated to be at $818 billion — almost 1% of the world’s GDP — yielding a potential diagnostic market of up to $1.6 billion. An accurate, affordable blood test will ease the burden of late-stage diagnosis on families and the health care system and facilitate the development of vaccines and targeted therapeutics.

hands with rose - NeuroQuest


Etai Gilboa, Chairman

NeuroQuest logo

Font Resize